Last updated: September 1, 2026
Daratumumab and hyaluronidase-fihj, marketed as Darzalex Faspro by Johnson & Johnson’s Janssen unit, is one of the largest products in multiple myeloma. Its commercial position rests on daratumumab’s broad treatment use, the convenience of subcutaneous administration, combination-regimen adoption, and a long U.S. biologic exclusivity period. J&J reported Darzalex sales of $9.744 billion in 2023, up from $7.977 billion in 2022. The product remained a major growth driver as treatment moved into earlier lines of multiple myeloma therapy. [1]
The main long-term risks are competition from intravenous and subcutaneous daratumumab alternatives, future biosimilar development, lower-cost multiple myeloma regimens, and the eventual loss of exclusivity after the early 2030s. Patent expiry dates are important, but the U.S. biologic exclusivity period and regulatory complexity create a larger barrier than any single formulation patent.
What is daratumumab and hyaluronidase-fihj?
Daratumumab and hyaluronidase-fihj is a fixed-dose co-formulation of the anti-CD38 monoclonal antibody daratumumab and recombinant human hyaluronidase PH20. Hyaluronidase temporarily modifies the extracellular matrix in subcutaneous tissue, allowing a large volume of antibody to be administered under the skin.
Darzalex Faspro is supplied for subcutaneous administration and is used in combination with other agents or as monotherapy in multiple myeloma. The product is also approved for systemic light-chain amyloidosis in specified treatment settings. [2]
| Attribute |
Darzalex Faspro |
| Active antibody |
Daratumumab |
| Delivery technology |
Recombinant human hyaluronidase-fihj |
| Originator |
Janssen Biotech, a Johnson & Johnson company |
| Initial U.S. approval |
May 2020 |
| Primary diseases |
Multiple myeloma; systemic light-chain amyloidosis |
| Administration |
Subcutaneous injection |
| Main comparator |
Intravenous Darzalex and other multiple myeloma regimens |
| U.S. biologic exclusivity reference point |
May 2032, subject to regulatory exclusivity rules |
| Commercial concentration |
Hematology, primarily multiple myeloma |
The subcutaneous product is distinct from intravenous Darzalex. Both contain daratumumab, but Darzalex Faspro adds hyaluronidase-fihj and uses a different delivery method.
How large is the Darzalex market?
Darzalex generated $9.744 billion in worldwide sales in 2023. Revenue increased by approximately 22% from 2022, when sales were $7.977 billion. The increase reflected greater use in newly diagnosed multiple myeloma, continued demand in relapsed disease, and adoption of combination regimens. [1]
| Year |
Darzalex sales |
Year-over-year change |
| 2021 |
$6.023 billion |
43.1% |
| 2022 |
$7.977 billion |
32.4% |
| 2023 |
$9.744 billion |
22.2% |
Darzalex Faspro is not separately disclosed as a standalone revenue line by Johnson & Johnson. Reported Darzalex revenue includes intravenous and subcutaneous presentations. The subcutaneous formulation is commercially important because it can reduce administration time and healthcare-resource use, but its exact contribution to total Darzalex sales is not publicly reported in J&J’s annual financial statements.
The product’s market value is supported by three factors:
- Daratumumab is used across several lines of multiple myeloma treatment.
- It is incorporated into multi-drug regimens rather than limited to a single niche indication.
- Subcutaneous delivery improves treatment logistics compared with prolonged intravenous infusion.
When does daratumumab lose exclusivity?
U.S. regulatory exclusivity and patent exclusivity should be analyzed separately.
U.S. biologic exclusivity
Darzalex Faspro received its first U.S. approval on May 1, 2020. Under the Biologics Price Competition and Innovation Act, a biosimilar generally cannot be approved until 12 years after the reference product’s first licensure, subject to statutory exceptions and FDA interpretation. The practical reference date is therefore May 1, 2032. [3,4]
The 12-year period does not mean that no competing product can reach the market before 2032 under any circumstance. A competing product could rely on a different regulatory strategy, challenge patents, or pursue a distinct product profile. The date is a central U.S. biosimilar approval constraint for products relying on Darzalex Faspro as the reference biologic.
Patent expiry
The key daratumumab composition patents originated before the approval of Darzalex Faspro and may have expiry dates earlier than the 2032 biologic-exclusivity date. Patent-term adjustment, patent-term extension, terminal disclaimers, continuations, and jurisdiction-specific prosecution can change the effective end date.
The product’s commercial protection is likely to depend on a layered estate involving:
- Daratumumab antibody and antigen-binding claims.
- Subcutaneous delivery using hyaluronidase.
- Fixed-dose or concentration-specific combinations.
- Administration schedules.
- Combination therapy for multiple myeloma.
- Treatment methods for systemic light-chain amyloidosis.
- Manufacturing and formulation claims.
Public patent databases and regulatory records should be reconciled before using any individual patent expiration date in a transaction, launch model, or litigation strategy. A composition patent expiry alone does not establish freedom to launch Darzalex Faspro.
What patents protect daratumumab and hyaluronidase-fihj?
The strongest commercial protection is likely distributed across the antibody, formulation, delivery, and method-of-use layers rather than concentrated in one patent.
Daratumumab antibody patents
Daratumumab is a human monoclonal antibody directed against CD38. Early patent families protect the antibody, binding regions, production methods, and therapeutic use. Some foundational antibody claims may expire before the product’s 12-year U.S. biologic exclusivity period.
Hyaluronidase delivery patents
Hyaluronidase-fihj is associated with Halozyme’s ENHANZE drug-delivery platform. Janssen and Halozyme entered into a collaboration covering subcutaneous delivery of selected biologic medicines. The relevant intellectual-property position may include platform patents, product-specific formulations, dosing systems, and combination claims. [5]
Halozyme’s delivery technology has commercial value because a competitor may need either a license or a separate delivery approach to replicate the same subcutaneous product profile. A daratumumab biosimilar delivered intravenously would not necessarily compete on identical administration economics.
Formulation and method-of-use patents
Potentially important claim categories include:
- Fixed-dose subcutaneous daratumumab and hyaluronidase compositions.
- Specific antibody concentrations and injection volumes.
- Treatment of newly diagnosed multiple myeloma.
- Treatment of relapsed or refractory multiple myeloma.
- Combination use with lenalidomide, bortezomib, dexamethasone, carfilzomib, pomalidomide, or other agents.
- Use in systemic light-chain amyloidosis.
- Dosing schedules and patient-selection criteria.
Method-of-use patents can create launch risk even when a competitor has designed around composition claims. Their practical value depends on claim scope, prescription patterns, labeling, induced-infringement exposure, and the ability to launch with a restricted label.
What is the Orange Book status of Darzalex Faspro?
Darzalex Faspro is a biologic, not a conventional small-molecule drug. The Orange Book is therefore not the principal U.S. patent listing system for this product. The relevant regulatory framework is the FDA’s Purple Book and the BPCIA patent-exchange process.
The distinction matters because:
- Small-molecule drugs generally rely on Orange Book patent listings.
- Biologics rely on reference-product exclusivity, biosimilar rules, patent disclosures, and BPCIA litigation.
- A conventional Orange Book-style “latest patent expiry” analysis is incomplete for Darzalex Faspro.
- Patent disputes may arise through the BPCIA process, declaratory litigation, or conventional patent litigation.
Which companies could challenge Darzalex Faspro?
The most credible future challengers are large biosimilar developers and manufacturers with monoclonal-antibody capabilities. Potential participants include Samsung Bioepis, Celltrion, Sandoz, Biocon Biologics, Fresenius Kabi, Amgen, Pfizer, Teva, and other companies with oncology-biosimilar infrastructure.
No company should be treated as a confirmed Darzalex Faspro challenger without a public biosimilar filing, patent-litigation complaint, settlement disclosure, or regulatory announcement. Public confirmation of a specific U.S. biosimilar application is generally limited because FDA application details are not fully disclosed before approval.
Biosimilar risk
Biosimilar development for daratumumab is technically feasible but commercially demanding. Developers must establish analytical similarity for a complex monoclonal antibody, conduct suitable clinical and pharmacology studies, and manage immunogenicity, manufacturing, and interchangeability issues.
The subcutaneous combination creates an additional question: a competitor may develop:
- An intravenous daratumumab biosimilar.
- A subcutaneous daratumumab product using a different hyaluronidase.
- A licensed product using the same or a related delivery platform.
- A separate fixed-dose combination that does not duplicate the originator formulation.
A biosimilar could initially enter through the intravenous market and later compete with the subcutaneous presentation. The competitive impact would depend on physician preferences, payer policy, site-of-care economics, and whether the biosimilar carries an interchangeable designation.
How does Darzalex Faspro compare with intravenous Darzalex?
| Issue |
Intravenous Darzalex |
Darzalex Faspro |
| Active antibody |
Daratumumab |
Daratumumab |
| Delivery |
Intravenous infusion |
Subcutaneous injection |
| Hyaluronidase |
No |
Yes |
| Administration burden |
Higher, particularly during initial dosing |
Lower relative administration time |
| Switching potential |
Can be replaced by subcutaneous formulation |
Can convert patients from intravenous therapy |
| Patent exposure |
Antibody and regimen patents |
Antibody plus formulation and delivery patents |
| Commercial role |
Established original presentation |
Convenience-oriented growth presentation |
Darzalex Faspro can protect the franchise even when older intravenous formulation patents weaken. It provides a product-level reason for prescribers and health systems to remain within the Janssen franchise, although a successful biosimilar could narrow the price differential.
What competitive drugs affect daratumumab revenue?
Daratumumab competes within a crowded multiple myeloma market. Key alternatives include:
- Isatuximab, marketed as Sarclisa by Sanofi, another anti-CD38 antibody.
- Lenalidomide and pomalidomide, marketed by multiple companies after generic entry.
- Bortezomib and carfilzomib proteasome inhibitors.
- Elotuzumab in selected combination settings.
- BCMA-directed therapies, including CAR-T products and bispecific antibodies.
- Autologous stem-cell transplantation and established multi-agent regimens.
Isatuximab is the closest pharmacologic competitor. BCMA-directed therapies create a different type of pressure because they can affect treatment sequencing, especially in heavily pretreated disease. Darzalex benefits from earlier-line use, where patient volumes are larger and treatment duration may be longer.
What generic launch risks exist for Darzalex Faspro?
A traditional generic launch is not the expected pathway. Darzalex Faspro is a biologic, so competition would generally arise through biosimilar or related-biologic pathways.
The principal launch scenarios are:
| Scenario |
Timing implication |
Commercial effect |
| No early biosimilar filing |
Before 2032 |
Darzalex retains strong pricing control |
| Intravenous daratumumab biosimilar |
After applicable patent and regulatory barriers |
Pressure begins in infusion settings |
| Subcutaneous biosimilar |
After product-specific barriers |
Greater direct pressure on Darzalex Faspro |
| Restricted-label biosimilar |
Potentially earlier or narrower entry |
Lower initial impact in patented indications |
| Settlement-based entry |
Agreement-specific |
Could establish a confidential or fixed launch date |
| Post-2032 broad entry |
After reference-product exclusivity |
Highest probability of multiple competitors |
The largest revenue risk is likely to emerge through a sequence rather than a single event: initial biosimilar entry in selected indications, payer-driven switching, price concessions, and later subcutaneous competition.
What litigation and settlement issues affect daratumumab?
As of the publicly reported information available through mid-2024, no widely disclosed U.S. settlement has established a definitive biosimilar launch date for Darzalex Faspro. The absence of a disclosed settlement does not eliminate future litigation risk.
Potential disputes may involve:
- Validity and infringement of antibody patents.
- Written-description and enablement challenges.
- Patent-term-adjustment calculations.
- Subcutaneous formulation claims.
- Hyaluronidase platform rights.
- Combination-treatment patents.
- Patent dance disclosures under the BPCIA.
- Induced infringement based on prescribing and labeling.
A settlement could materially change the launch timeline without invalidating the asserted patents. For valuation, a probability-weighted model should separate patent invalidity, noninfringement, settlement, and delayed-entry outcomes.
How strong is the Darzalex Faspro patent estate?
The estate is commercially strong but not uniform across all claim categories.
| Protection layer |
Relative strength |
Main issue |
| Biologic exclusivity |
High through the statutory period |
Applies to the reference product, not all competing products |
| Core antibody patents |
Historically important |
Earliest patents may expire before 2032 |
| Hyaluronidase platform |
Potentially high |
Licensing and design-around questions |
| Fixed-dose formulation |
High if claims survive |
Vulnerable to validity and noninfringement challenges |
| Method-of-use patents |
Variable |
Depends on label and treatment practice |
| Manufacturing patents |
Variable to high |
Difficult to assess without claim-by-claim review |
| Combination-regimen patents |
Mixed |
Commercial relevance varies by indication |
The strongest barrier is the combination of regulatory exclusivity, manufacturing complexity, delivery know-how, and a broad clinical label. The weakest point is likely to be the aging of foundational antibody patents before the end of the biologic-exclusivity period.
What is the financial trajectory for daratumumab and hyaluronidase-fihj?
Darzalex revenue is likely to continue growing in the near term, but the growth rate should moderate as the product reaches a larger revenue base and faces more mature-market competition.
The main growth drivers are:
- Earlier-line treatment adoption.
- Use in transplant-eligible and transplant-ineligible newly diagnosed patients.
- Continued expansion of combination regimens.
- Subcutaneous conversion from intravenous administration.
- Use in systemic light-chain amyloidosis.
- Growth in international markets.
The main risks are:
- Treatment sequencing changes from BCMA therapies.
- Reimbursement pressure from combination regimens.
- Generic pricing of backbone therapies.
- Future biosimilar competition.
- Patent litigation and settlement uncertainty.
- Erosion in older indications as competitors enter.
Darzalex’s revenue profile differs from a short-course oncology product because multiple myeloma treatment can continue over extended periods. That supports recurring revenue, but it also exposes the product to cumulative payer pressure and regimen substitution.
Key Takeaways
- Darzalex, including Darzalex Faspro, generated $9.744 billion in 2023 sales, up 22.2% from 2022.
- Darzalex Faspro is the subcutaneous daratumumab and hyaluronidase-fihj product developed by Janssen.
- The product’s first U.S. approval was May 1, 2020, creating a key U.S. biologic-exclusivity reference date of May 2032.
- Patent protection is layered across the antibody, delivery platform, formulation, manufacturing process, and treatment methods.
- Darzalex Faspro is governed primarily by biologic and Purple Book frameworks, not the conventional Orange Book system.
- Isatuximab is the closest antibody competitor; BCMA-directed therapies create broader treatment-sequencing risk.
- The first major competitive event could be an intravenous daratumumab biosimilar, followed later by direct subcutaneous competition.
- Darzalex revenue should remain substantial before 2032, but growth is likely to slow as the product matures and pricing pressure increases.
FAQs About Daratumumab and Hyaluronidase-Fihj
Is Darzalex Faspro the same as Darzalex?
No. Both contain daratumumab, but Darzalex is the intravenous product and Darzalex Faspro combines daratumumab with hyaluronidase-fihj for subcutaneous administration.
Does hyaluronidase-fihj have independent commercial value?
Yes. Hyaluronidase-fihj enables subcutaneous delivery of a large-volume antibody dose and may create licensing, formulation, and platform-IP barriers separate from the daratumumab antibody.
Can a daratumumab biosimilar automatically replace Darzalex Faspro?
No. Automatic substitution depends on the product’s regulatory designation, including whether it is designated interchangeable, and on the laws and payer policies of the relevant jurisdiction.
Will a daratumumab biosimilar necessarily include hyaluronidase?
No. A biosimilar developer could initially pursue intravenous daratumumab or develop a subcutaneous product using a different delivery technology.
Which geographic market will face competition first?
The timing will vary by jurisdiction because patent terms, regulatory exclusivity, biosimilar rules, and litigation differ across the United States, European Union, Japan, and other markets.
References
- Johnson & Johnson. (2024). 2023 annual report. https://www.jnj.com
- U.S. Food and Drug Administration. (2024). Darzalex Faspro prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003.
- Halozyme Therapeutics, Inc. (2024). 2023 annual report. https://investor.halozyme.com
